Wedbush Equities Analysts Boost Earnings Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Wedbush lifted their Q3 2024 earnings estimates for Stoke Therapeutics in a research note issued to investors on Wednesday, August 7th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.49) per share for the quarter, up from their previous forecast of ($0.54). Wedbush currently has a “Outperform” rating and a $17.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.37) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q4 2024 earnings at ($0.51) EPS, FY2024 earnings at ($2.03) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($2.07) EPS and FY2028 earnings at ($0.77) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.11. The firm had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.33 million.

Several other equities analysts have also weighed in on STOK. Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Trading Up 2.0 %

Shares of NASDAQ STOK opened at $14.42 on Friday. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $17.58. The firm’s 50-day moving average is $14.47 and its 200-day moving average is $11.27. The firm has a market capitalization of $751.57 million, a PE ratio of -5.98 and a beta of 0.87.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the transaction, the insider now owns 2,485 shares of the company’s stock, valued at $34,168.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 11.30% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the company. Quest Partners LLC acquired a new stake in Stoke Therapeutics in the 2nd quarter valued at approximately $29,000. Nisa Investment Advisors LLC lifted its position in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Stoke Therapeutics during the 2nd quarter worth about $123,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Stoke Therapeutics during the 1st quarter worth about $141,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after acquiring an additional 6,636 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.